Royal College of Surgeons in Ireland
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma....pdf (1.44 MB)

Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets

Download (1.44 MB)
journal contribution
posted on 2023-11-13, 17:06 authored by Yinshuang ChenYinshuang Chen, Weipeng Wang, Maria MorganMaria Morgan, Tracy RobsonTracy Robson, Stephanie AnnettStephanie Annett
Obesity is a global epidemic and overwhelming evidence indicates that it is a risk factor for numerous cancers, including hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide. Obesity-associated hepatic tumorigenesis develops from nonalcoholic fatty liver disease (NAFLD), progressing to nonalcoholic steatohepatitis (NASH), cirrhosis and ultimately to HCC. The rising incidence of obesity is resulting in an increased prevalence of NAFLD and NASH, and subsequently HCC. Obesity represents an increasingly important underlying etiology of HCC, in particular as the other leading causes of HCC such as hepatitis infection, are declining due to effective treatments and vaccines. In this review, we provide a comprehensive overview of the molecular mechanisms and cellular signaling pathways involved in the pathogenesis of obesity-associated HCC. We summarize the preclinical experimental animal models available to study the features of NAFLD/NASH/HCC, and the non-invasive methods to diagnose NAFLD, NASH and early-stage HCC. Finally, since HCC is an aggressive tumor with a 5-year survival of less than 20%, we will also discuss novel therapeutic targets for obesity-associated HCC and ongoing clinical trials.


RCSI/SU StAR PhD programme

Psoriasis Foundation, USA

National Children's Research Centre (C/18/9)

SFI Strategic Partnership Programme - Precision Oncology Ireland (18/SPP/ 3522)

SFI-FFP program (20/FFP-A/8361)



The original article is available at

Published Citation

Chen Y, Wang W, Morgan MP, Robson T, Annett S. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets. Front Endocrinol (Lausanne). 2023;14:1148934.

Publication Date

8 June 2023

PubMed ID



  • School of Pharmacy and Biomolecular Sciences

Research Area

  • Immunity, Infection and Inflammation
  • Endocrinology
  • Vascular Biology
  • Cancer


Frontiers Media SA


  • Published Version (Version of Record)